Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Amneal Pharmaceuticals

Amneal Pharmaceuticals (NASDAQ: AMRX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Amneal Pharmaceuticals reported 7 open-market sales of 629,691 shares ($9.8m) and 0 open-market purchases, by 5 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Amneal Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
17 September 2026Buchi J KevinDirectorGift−20,445—75,077Form 4
11 September 2026Buchi J KevinDirectorOption exercise+20,445$14.4595,522Form 4
1 September 2026Boyer Andrew SExecutive Vice PresidentGift−80,000—193,646Form 4
21 August 2026Boyer Andrew SExecutive Vice PresidentGift−152,426—273,646Form 4
13 August 2026Kiely JohnDirectorOpen-market sale−50,000$17.64210,252Form 4
13 August 2026Kiely JohnDirectorGift−10,000—200,252Form 4
12 August 2026Daly Jason B.EVP, Chief Legal OfficerOpen-market sale−210,000$17.4035,171Form 4
12 August 2026Shah NikitaExecutive Vice PresidentOpen-market sale−146,403$17.51253,390Form 4
11 August 2026Buchi J KevinDirectorOption exercise−168,573$17.1893,499Form 4
11 August 2026Daly Jason B.EVP, Chief Legal OfficerOpen-market sale−6,613$17.70245,171Form 4
10 August 2026Patel Tushar Bhikhubhai—Grant or award+12,763,469—61,341,678Form 4
10 August 2026Patel Chirag K.President & Co-CEOGrant or award+6,381,734—6,381,734Form 4
10 August 2026Patel GautamDirectorGrant or award+283,632—283,632Form 4
10 August 2026Patel ChintuCo-CEOGrant or award+6,381,734—6,381,734Form 4
11 May 2026Autor Deborah M.DirectorOpen-market sale−34,819$12.9493,660Form 4
7 May 2026Yanai ShlomoDirectorOption exercise+34,819—320,804Form 4
7 May 2026Meister Paul MDirectorOption exercise+48,747—832,800Form 4
7 May 2026Nark Ted CDirectorOption exercise+34,819—325,848Form 4
7 May 2026Kiely JohnDirectorOption exercise+34,819—260,252Form 4
7 May 2026Patel GautamDirectorOption exercise+34,819—1,643,963Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Amneal Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.